Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With … (NCT00238368) | Clinical Trial Compass
CompletedPhase 2
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
United States59 participantsStarted 2004-02
Plain-language summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy with an autologous stem cell or bone marrow transplant may allow more chemotherapy to be given so that more cancer cells are killed. Procedures, such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) (done during chemotherapy) may help doctors predict a patient's risk of relapse and help plan the best treatment.
PURPOSE: This phase II trial is studying how well FDG-PET works in predicting risk of relapse in patients with aggressive non-Hodgkin's lymphoma who are undergoing combination chemotherapy with or without autologous stem cell or bone marrow transplant.
Who can participate
Age range
18 Years – 120 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following subtypes:
* Diffuse large B-cell lymphoma
* Mediastinal (thymic) B-cell lymphoma
* Grade 3 follicular lymphoma
* Anaplastic large cell lymphoma
* Peripheral T-cell lymphoma
* Must have adequate staging of disease by the following techniques:
* CT scan or MRI of affected sites
* Bone marrow biopsy (in cases where results influence the duration of chemotherapy only)
* Lumbar puncture (if clinically indicated)
* Stage I-IV disease
* Any International Prognostic Index risk category
* Radiographically measurable disease
* None of the following aggressive non-Hodgkin's subtypes are allowed:
* Mantle cell lymphoma
* Lymphoblastic lymphoma
* Burkitt's lymphoma
* Mycosis fungoides/Sezary's syndrome
* HTLV-1-associated T-cell leukemia/lymphoma
* Primary CNS lymphoma
* HIV-associated lymphoma
* Transformed lymphomas
* No prior diagnosis of another hematologic malignancy
* No known progressive disease during prior first-line chemotherapy
* No active CNS involvement by lymphoma, except CNS involvement at diagnosis that is previously treated and in remission
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* ECOG 0-4 (0-2 for peripheral blood stem cell \[PBSC\] or bone marrow transplantation \[BMT\] patients)
Life expectancy
* Not specified
Hematopoietic
* Absolute neutrophil count \> 1,000/mm\^3\*
* Platelet count ≥ 75,000/mm…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
2-year event free survival
Trial details
NCT IDNCT00238368
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins